THE FASTEST GROWING
Aquaculture now accounts for more than 50% of the fish that we eat. Yet as fish farming has intensified, so too have the challenges.
Recent years have seen astronomical losses across farmed species. The problem is made worse by inefficient delivery of essential compounds and nutrients. This over-use can also be polluting, erasing important gains achieved by otherwise environmentally-conscious aquaculture practices.
Collectively, billions of dollars in both direct and indirect damages result every year.
ANNUAL MARKET VALUE
CAGR: > 5%
While there is no one-size fits all solution, we believe we’ve come up with the next best thing. BioFeyn is pioneering a targeted, modular, delivery mechanism (what we call a “Feyn”) for compounds and nutrients that can be adapted to meet the most critical needs in the industry. The process is a simple one:
RELEASE & ACTION
We formulate the Feyn to prepare specialized and targeted blends
These purpose-built Feyns are
integrated into feed pellets
Enhanced feed is consumed, the Feyns released, and compounds delivered to targets
Delivering better health, better
sustainability, better profit
BioFeyn is committed to making a positive impact. Our technology addresses aquaculture sustainability challenges in a direct way by reducing waste and promoting the use of environmentally-friendly ingredients.
The BioFeyn team includes a materials engineer, a molecular biologist, and medical doctor. We share a common belief that solutions of the future will be driven by the translational application of science for the benefit of both people and the planet.
TIMOTHY BOULEY, CEO
Medical doctor and environmental scientist. Previously led programs at World Bank on climate change, health, infectious disease, oceans, and fisheries. Researcher at UCSF, US Nat Acad of Sciences, World Health Organization. Degrees from Oxford, Duke, Harvard, and Tufts.
UMBERTO MARTINO, CTO
Materials engineer with a focus in bio-nanotechnology and nanosensors. Spent 5 years in four countries building innovative nanotech-based solutions for early diagnosis and treatment of cancer. PhD from University of Paris and BFC certificate from INSEAD.
MARIE-CHRISTINE IMBERT, COO
Molecular biologist. Previously Manager of Private Equity Risk and co-founder of LGT and Science Program at LGT Capital Partners. Co-founder, Sober-Life Addiction Treatment App. Advisor to Global Changemakers, HEYA Palestine. PhD from the MRC-LMB at Cambridge University.